Kornimate/medical-research-clean huggingface dataset:
prewarming effect in preventing perioperative hypothermia

Conditions: Hypothermia

Summary: perioperative hypothermia brings numerous and recognized postoperative complications. active warming intraoperatively helps to maintain body temperature in the postoperative period, but there are few studies in brazil, assessing the effect of prewarming in maintaining normothermia. it is believed that prewarming with forced air warming system keep the body temperature during intra and post-operative. this study aims to evaluate the effect on prewarming maintaining body temperature of patients undergoing elective surgery of gynecology specialty using the forced air warming system. the study is experimental design, controlled type randomized clinical trial, with simple blinding for patients. eighty adult patients undergoing gynecological surgery in the art, with a surgical time of at least an hour will be randomized and allocated into experimental groups - prewarming system with forced air warming system for 20 minutes, and control - prewarming with sheet and blanket for 20 minutes. the patients will be kept warm during the anesthetic-surgical procedure. the measurement of temperature will be using a tympanic thermometer. participants will be followed from receiving the surgical center to the end of surgery. data will be recorded in validated instrument. data analysis will be used the model linear mixed effects and the structure error auto-regressive.

maintaining the patient in the perioperative normothermia is a challenge for surgical and nursing staff. despite advances in the development of new technologies for the prevention of perioperative hypothermia, this event still happens in the operating room of the health services to prevent patient's body temperature loss, passive and active cutaneous warming methods can be used. passive methods prevent loss of body heat through the heat transfer block, as blankets, clothes and cotton sheets; however, there is evidence to show that although assist in maintaining body temperature, passive methods alone are not effective. active warming methods are effective in keeping the perioperative normothermia. among the different technologies available we emphasize the circulating water mattress, the forced air warming system and the carbon fiber resistive heating blankets. based on these and due to the lack of research in the brazilian reality on effective measures for the prevention of perioperative hypothermia, among these, prewarming, and the finding guided by the professional experience that just directed investment for the maintenance of body temperature patient in the perioperative period, in health services, justified the conduct of this study.

Eligibility criteria:
inclusion criteria: * aged 18 years; * undergoing elective surgery with duration of at least one hour in the gynecological specialty with open technique; * under general, regional or combined anesthesia. exclusion criteria: * patients with a body temperature above or below 36oc 37,5oc at the reception of the operating room.

Keywords: hypothermia perioperative nursing prewarming prevention and control
azithromycin to prevent wheezing following severe respiratory syncytial virus (rsv) bronchiolitis

Conditions: RSV Bronchiolitis

Summary: this trial is a proof-of-concept pilot study aim to investigate the biologic and clinical effects of early azithromycin treatment in children hospitalized with respiratory syncytial virus (rsv) bronchiolitis. hypotheses in infants hospitalized with rsv bronchiolitis, azithromycin therapy (compared to placebo) will result in: 1. decreased concentrations of inflammatory mediators (il-8 as primary outcome) in serum and nasal wash measured on day 8 after randomization. 2. a smaller proportion of participants with recurrent (≥2) wheezing episodes during weeks 3-52 following randomization.


Eligibility criteria:
inclusion criteria: 1. age: 1-18 months. 2. hospitalization for the first episode of rsv bronchiolitis: * confirmed rsv infection by positive nasal swab results (viral culture and/or direct antigen detection) from the slch virology lab; and * at least two of the following symptoms/signs of bronchiolitis: respiratory rate greater than 40 breaths/minute; cough; wheezing; audible rales, crackles, and/or rhonchi; paradoxical chest movements (retractions). 3. duration of respiratory symptoms from initiation of symptoms to admission is 5 days or less. time of admission will define by the time the child was seen in the ed for the visit that led to hospitalization. 4. randomization can be performed within 48 hours from time of admission (defined by time of first set of vital signs obtained on the floor). 5. willingness to provide informed consent by the child's parent or guardian - exclusion criteria: 1. prematurity (gestational age \< 36 weeks). 2. presence or history of other significant disease (cns, lung, cardiac, renal, gi, hepatic disease, hematologic, endocrine or immune disease). children with atopic dermatitis will not be excluded from the study. 3. clinically significant gastroesophageal reflux currently treated with a daily anti-reflux medication (anti- h2 or ppi). 4. the child has significant developmental delay/failure to thrive, defined as weight \< 3% for age and gender. 5. history of previous (before the current episode) wheeze or previous treatment with albuterol. 6. treatment (past of present) with corticosteroid (systemic or inhaled) and/or montelukast. 7. treatment with any antibiotics in the past 2 weeks. 8. treatment with macrolide antibiotic (azithromycin, clarithromycin or erythromycin) with the past 4 weeks. 9. current treatment with any daily medication (other then albuterol, vitamins or nutritional supplements). 10. participation in another clinical trial. 11. evidence that the family may be unreliable or nonadherent, or may move from the clinical center area before trial completion. 12. contraindication of use of azithromycin or any other macrolide antibiotics.
the association between the distributions mch and rbc, and mortality in hemodialysis patients

Conditions: Renal Anemia

Summary: patients were classified into two groups based on the values of mch and rbc, patients with mch ≥30 pg but \ 350×104/μl. associations between all-cause mortality and the distributions of mch and rbc were assessed by kaplan-meier curves and cox proportional hazards regression model.

the hb levels generally provides the value of rbc and iron status because mean corpuscular hemoglobin mch is derived from the hb divided by rbc. mch depends on the size and concentration of erythrocytes. thus, the value of rbc and mch depend on dose of esa and iron, respectively. guidelines for renal anemia in chronic kidney disease of 2015 japanese society for dialysis therapy recommend administration hemoglobin (hb) levels ≥10 g/dl but \<12 g/dl in dialysis patients.patients whose hb levels is maintained at 10 to 12 g/dl, hb levels is widely distributed when divided into rbc and mch. therefore, the investigators examined the prognosis of life in the distribution of mch and rbc.

Eligibility criteria:
inclusion criteria: * patients will be controlled with hemoglobin levels between ≥10 g/dl and \ 1 year. exclusion criteria: * patients will be excluded if they have peritoneal dialysis combined with hd, do not have records of laboratory investigations during this period, or are transferred to another hospital or lost to follow-up.

Keywords: red blood cell mean corpuscular hemoglobin hemoglobin hemodialysis patients
triamcinolone or bevacizumab for central retinal vein occlusion with poor vision

Conditions: Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity

Summary: to evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (crvo) presenting poor visual acuity.


Eligibility criteria:
inclusion criteria: * central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion exclusion criteria: * previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset * patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders * neovascularization on the disc or elsewhere or rubeosis

Keywords: bevacizumab,triamcinolone, intravitreal injection
study of efficacy and safety of qaw039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma

Conditions: Asthma

Summary: a randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of qaw039, compared with placebo, when added to standard-of-care (soc) asthma therapy in adult and adolescent (≥ 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second (fev1) at the end of 12 weeks of treatment.


Eligibility criteria:
inclusion criteria: * a diagnosis of asthma (according to gina 2016) for a period of at least 6 months. * treated with medium dose inhaled corticosteroid (ics), or high dose ics, or low dose ics plus long- acting beta agonist (laba), or low dose ics plus leukotriene receptor antagonist (ltra), or medium dose ics plus laba for at least 3 months prior to visit 1 and the doses have been stable for at least 4 weeks prior to visit 1. * fev1 of ≤85% for patients aged ≥18 years. fev1 of ≤90% for patients aged 12 to \<18 years. * daytime asthma symptom score (0 to 6 scale) of ≥1 per day during 4 of the last 7 days of the placebo run- in period. * total daily saba use ≥1 puff per day during 4 of the last 7 days of the placebo run-in period. * demonstrated reversible airway obstruction. * asthma control questionnaire (acq) score ≥ 1.5. exclusion criteria: * use of other investigational drugs within 5 half-lives of enrollment, or within 30 days, whichever is longer. * a resting qtcf (fridericia) ≥450 msec (male) or ≥460 msec (female). * pregnant or nursing (lactating) women. * serious co-morbidities. * patients on \>20 mg of simvastatin, \> 40 mg of atorvastatin, \>40 mg of pravastatin, or \>2 mg of pitavastatin. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: qaw039, uncontrolled asthma
physical activity and first degree female relatives of breast cancer patients

Conditions: Female; First-degree Relative With Breast Cancer

Summary: the purpose of this study is to learn more about encouraging physical activity among first degree female relatives of women with breast cancer. physical activity can decrease a woman's risk of developing breast cancer, on average, by 20%; however, physical activity interventions have not been developed specifically for first degree female relatives of cancer patients, so currently, it is unknown whether standard physical activity interventions are sufficient for these women or if first degree female relatives would benefit from an enhanced physical activity intervention that addresses information about breast cancer risk reduction. to obtain information about first degree female relatives preferences for a physical activity intervention, this study seeks to have first degree female relatives of breast cancer patients enroll in a standard physical activity intervention developed for healthy men and women. after completion of the three month intervention, the women will be asked to participate in two, one-hour long focus group with 5-7 other participants. the first focus group is to discuss aspects of the physical activity intervention that they liked and did not like, as well as things they think may have enhanced the intervention and made it more relevant to other first-degree relative of breast cancer patients. in the second focus group, participants will be shown enhancements that were developed based on information gathered from the first focus group. participants will be asked for their feedback on the newly developed enhancements.


Eligibility criteria:
inclusion criteria: * aged 18 to 65 * have a mother, sister, or daughter who was diagnosed with breast cancer * have not been diagnosed with any type of cancer except basal cell carcinoma * able to speak and read english * sedentary, defined as engaging in less than 90 minutes of moderate-intensity physical activity each week exclusion criteria: * current of planned pregnancy for next 3 months * presence of a known medical condition that would make physical activity unsafe * history of a severe psychiatric illness * plans to move from the area in the next 3 months.
rt-pcr sars-cov-2 at 1 month of covid-19 infection in the geriatric population

Conditions: Covid-19

Summary: evaluation of the rate of positive rt-pcr sars-cov-2 test at 1 month of covid infection among elderly people. it is unclear how long an individual with covid-19 will remain "sick" and "contagious". it appears that sars-cov-2 can be transmitted before symptoms appear and throughout the course of the disease. they investigators did not find any study on a covid + geriatric population reassessing carriage at 1 month even though age seems to be a risk factor for prolonged excretion as suggested in the study following study: xu k, chen y, yuan j, yi p, ding c, wu w, et al. factors associated with prolonged viral rna shedding in patients with covid-19. clinical infectious diseases. 2020 apr 9; ciaa351


Eligibility criteria:
inclusion criteria: * age\> 70years * patient hospitalized on the geriatric center from march 1, 2020 to august 1, 2020 with a diagnosis of covid-19 still alive at 1 month. * patient having agreed to the re-use of their data for the purposes of this research exclusion criteria: * subject who expressed his opposition to participate in the study * subject under judicial protection

Keywords: rt-pcr sars-cov-2 covid-19 carriage viral shredding elderly elderly people geriatric
descriptive study of acute spontaneous spinal cord infarction

Conditions: Spinal Cord Infarction; Spinal Cord Stroke; Vascular Myelopathy

Summary: acute spontaneous spinal cord infarctions (sci) are an uncommon cause of myelopathy (5%), but their prognostic is heterogeneous and frequently severe. positive diagnosis is difficult, one quarter of initial mris are normal. differential diagnosis with other transverse myelopathy causes is a common issue. as in cerebral stroke, there are multiple causes and mechanisms in spontaneous sci, often difficult to clearly establish. there are also clinical and radiological patterns, sometimes misleading, according to vascular territory and its expanse. due to its scarcity and heterogeneity, improving knowledge and medical care remains difficult. medical care is still badly codified in medical literature. recently, diagnostic criteria have been proposed to better identify sci, provide earlier care and homogenize future research. external validity and reproduction of these new criteria among acute myelopathies are still to be validated. while there is no established medical treatment in the initial care of spontaneous sci, some case reports show successful treatment with iv thrombolysis. given the severe prognosis, conventional treatment of strokes (thrombolysis, anticoagulant and antiplatelet), could be considered on an individual scale, in a specific protocol. a better knowledge of radio-clinical and security factors are necessary to support this approach. in order to respond to these difficulties, a retrospective cohort will allow us to better define epidemiological, clinico-radiological and prognostic features of spontaneous sci. it lays the foundation of a possible prospective multicentric cohort, necessary for specific therapeutic studies.


Eligibility criteria:
inclusion criteria: * hospitalized patients in a medical ward in montpellier and nîmes university hospitals with registered diagnosis of vascular myelopathy * and final diagnosis of spontaneous sci after reviewing medical datas exclusion criteria: * non ischemic myelopathies : compression, hematomyelia, spinal davf, intramedullary tumor, inflammatory, infectious or post-infectious myelitis, post-radiation myelopathy,...) * secondary sci : sci following an aortic, cardiac or rachidian surgery, extracorporeal circulation, post-hemodynamic shock * sci without a cause

Keywords: neurology vascular disease paraplegia quadriplegia
dual use approach bias training for nicotine addiction

Conditions: Tobacco Smoking; Electronic Cigarette Use; Substance Use

Summary: the present project will evaluate the initial efficacy of approach bias retraining among dual combustible cigarette (cc) and electronic cigarette (ecig) users. the study employs a randomized controlled design to follow 90 experienced dual cc/ecig users motivated to quit nicotine as they engage in a self-guided quit attempt following approach bias retraining.

the study employs a randomized controlled design to follow 90 experienced dual cc/ecig users motivated to quit nicotine as they engage in a self-guided quit attempt following approach bias retraining. participants will be randomized to one of three approach bias retraining conditions: (1) cc+ecig; (2) cc only; or (3) sham (control). participants will complete a phone pre-screener, baseline (week 1 of study participation), 4 approach bias retraining sessions in laboratory (with quit day scheduled for the 4th session; weeks 2-5 of study participation), and follow-up assessments at 4- and 6-weeks post-intervention (i.e., weeks 9 and 11 of study participation, respectfully). participants also will complete ecological momentary assessments (ema) of cc smoking, ecig use, and cc and ecig urges/cravings for 14 days post-intervention (i.e., weeks 5-7 of study participation) on internet capable smartphones. the only time data will be collected is when participants complete ema assessments or follow up surveys using the redcap app on the smartphone.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * at least 15 days of cc use for the previous month * ecig use with nicotine at least 15 days for the previous month * motivation to quit nicotine (both cc and ecig; ≥ 5 on a 0-10 scale) * ability to speak and read english fluently * not have decreased number of cigarettes by more than half in the past month * own an android smartphone (for ema). exclusion criteria: * current psychotherapy or pharmacotherapy for mental illness or addiction * current use of nicotine replacement therapy, zyban, or chantix * limited mental capacity or inability to provide informed consent * insufficient command of the english language (\>6th grade english literacy level required)
nuwiq for perioperative management of patients with haemophilia a on emicizumab regular prophylaxis study

Conditions: Severe Hemophilia A

Summary: recombinant factor viii for the prevention of bleeding in patients with severe haemophilia a undergoing major surgery while receiving emicizumab prophylaxis

patients with severe haemophilia a receiving emicizumab will often need concomitant fviii to provide haemostatic cover during major surgery. this prospective, open-label, uncontrolled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of nuwiq, a recombinant factor viii, in combination with emicizumab prophylaxis in male patients over 12 with severe haemophilia a undergoing major surgery.

Eligibility criteria:
inclusion criteria: * severe haemophilia a (fviii activity \[fviii:c\] \<1%) according to medical history * male patients at least 12 years of age * previous treatment with any fviii product(s) for at least 150 exposure days * on regular prophylaxis with emicizumab for at least 1 month prior to a scheduled major elective surgery requiring fviii treatment * freely given written informed consent of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations exclusion criteria: * coagulation disorder other than haemophilia a * present or past fviii inhibitor (≥0.6 bethesda units \[bu\]/ml) according to medical history * severe liver or kidney disease (alanine aminotransferase \[alt\] and/or aspartate aminotransferase \[ast\] levels \>5 times the upper limit of normal; or creatinine \>120 μmol/l) * known hypersensitivity to nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188) * already had surgery in this study * current participation in another interventional clinical trial * treatment with any investigational medicinal product (imp) within 30 days prior to screening visit
exosurf neonatal and survanta for treatment of respiratory distress syndrome

Conditions: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Bronchopulmonary Dysplasia

Summary: the purpose of this study is to compare the efficacy of two surfactants, exosurf neonatal (burroughs wellcome co.) and survanta (ross laboratories), for the treatment of neonatal respiratory distress syndrome.

the nichd neonatal research network conducted a randomized trial at 11 centers comparing the efficacy of two surfactants -- exosurf neonatal (burroughs wellcome co.) and survanta (ross laboratories) -- for the treatment of neonatal respiratory distress syndrome. newborn infants with birth weights of 501-1500g with respiratory distress syndrome who were receiving assisted ventilation with 30% oxygen or more within 6 hours of birth were enrolled between january 1991 and january 1992. infants were randomly assigned to receive up to four intratracheal doses of either exosurf neonatal or survanta.

Eligibility criteria:
inclusion criteria: * newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were receiving assisted ventilation with 30% oxygen or more exclusion criteria: * less than 6 hours of age

Keywords: nichd neonatal research network extremely low birth weight (elbw) prematurity respiratory distress syndrome surfactant
various serving sizes of lentils on blood glucose and insulin

Conditions: Healthy

Summary: the purpose of this study is to assess the effects of consuming either 1/2 or 1/4 cup servings of lentils on post-prandial blood glucose and insulin as compared to 4 types of starchy foods (corn, macaroni, white potato, white rice).

eligible participants will undergo a total of 6 study visits. during each visit, a fasted blood sample will be taken by fingerprick, and approximately 500 µl of blood will be dripped into a collection tube. the participant will then consume a meal of either: two types of lentils, corn, macaroni, white rice, or white potato. all study days will be randomized. each meal will be served in either 1/4 or 1/2 cup servings depending on the study block. six more blood samples will be taken by fingerprick at 15, 30, 45, 60, 90 and 120 minutes after the beginning of the meal.

Eligibility criteria:
inclusion criteria * healthy men and women * age 18-40 years * body mass index (bmi) 20-30 kg/m2 exclusion criteria: * tobacco use * pregnant or breastfeeding * fasting blood glucose ≥ 7.0 mmol/l * two hour blood glucose ≥ 11.1 mmol/l after consuming 75g glucose drink (oral glucose tolerance test beverage) * any major medical condition including a history of aids or hepatitis * medical or surgical event requiring hospitalization within 3 months of randomization * any medications except a stable dose (3 months) of oral contraceptives, blood pressure or statin medications * blood pressure \>140/90 mm hg * natural health products (nhps) used for glycemic control * probiotic supplements * dietary fibre supplements * consumption of \>4 servings of pulses per week * food allergy or non-food life threatening allergy * shift workers * alcohol consumption \>14 drinks/week or \>4 drinks/sitting * recent or intended significant weight loss or gain (\>4 kg in previous 3 months) * elite athletes

Keywords: lentils diabetes glycemia insulin glucose